Key facts
- Notable investors include Arben Ventures, Heartfelt (Private Equity), Underdog Labs.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Trias Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Trias Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Trias Bio
Developer of engineering technologies designed to optimize RNA sequences for improved therapeutic applications. The company's platform utilizes large language models and computational biology to accelerate sequence design and analysis, enabling biotechnology researchers to understand and improve the development of RNA-based therapeutics.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 5
- Website
- triasbio.com/
- Ownership
- Privately Held (backing)
Trias Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trias Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trias Bio in its N-PORT filings yet. We sweep new filings monthly.